Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2000
05/30/2000US6069234 Factor xa containing epidermal growth factor-like domains and with its light protein chain truncated at n- and c-terminals; for use in crystallographic inhibition studies for designing new anticoagulants
05/30/2000US6069232 Polyfluoroalkyl tryptophan tripeptide thrombin inhibitors
05/30/2000US6069231 Amino acid sequences of domains found in transcription factors including a mammalian retinoblastoma-interacting zinc finger protein; for fusion proteins useful for regulating transcription of target genes; diagnosis of related diseases
05/30/2000US6069230 High level expression and facile purification of proteins, peptides and conjugates for immunization, purification and detection applications
05/30/2000US6069229 Mammalian proteinases; oxidoreductases; related reagents
05/30/2000US6069193 Administering an effective amount of transferrin to a mammal suffering from type ii diabetes mellitus
05/30/2000US6069135 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents
05/30/2000US6069134 Methods and compositions comprising DNA damaging agents and p53
05/30/2000US6069133 Targeted delivery of genes encoding interferon
05/30/2000US6069130 Prodrugs useful in vivo or invitro for preventing or treating coagulation disorders
05/30/2000US6069129 Elastin derived composition and method of using same
05/30/2000US6069127 Human infant formula containing a glycoprotein specific for binding to the human mac-2 (macrophage antigen) lectin; to prevent infections
05/30/2000US6069126 Administering a pneumocandin derivative with an antifungal agent such as azole, polyene, nucleotide inhibitor, mannan inhibitor, protein elongation factor inhibitor or bactericidal/permeability increasing protein
05/30/2000US6069008 Antisense modulation of NF-kappa-B p65 subunit expression
05/30/2000US6069007 Mammalian cell transformed in vitro with a ribozyme able to cleave human immunodeficiency virus rna; for treatment of acquired immune deficiency syndrome
05/30/2000US6069006 Connective tissue growth factor (CTGF) regulatory nucleic acid sequences
05/30/2000US6069001 Nucleotide sequence; for use in diagnosis of cancer and melanoma; for use in human leukocyte antigen typing for grafts and transplants
05/30/2000US6068984 Separating hb15 prositive cells from population of unrelated cells by reacting antibody that specifically binds the extracellular, transmembrane or cytoplasmic domain of the glycoprotein, then isolating cells
05/30/2000US6068983 Introducing into cells a dna molecule coding for an fc receptor which is then expressed for increased phagocytic activity; combating infection and/or modulating immune complex disease
05/30/2000US6068976 Nucleotide sequences of control region of human obesity gene; for screening modulators of gene expression to treat hypertension, cardiovascular diseases, diabetes, infertility, obesity, anorexia, cachexia, and other eating disorders
05/30/2000US6068975 Isolation and uses of a Wilson's disease gene
05/30/2000US6068973 Suppressing transmission of influenza a virus to cell by contacting cell with influenza virus peptide of specific sequence chosen by a computer algorithm
05/30/2000US6068972 Screening by contacting microorganisms with organic solvent, determining expression of acr-like efflux pump gene locus, comparing to control, altered expression indicates activation of multiple antibiotic resistance phenotype
05/30/2000US6068858 Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
05/30/2000US6068850 A stable aqueous formulation of a peptide related compound comprising atleast one peptide compoun and water, wherein the formulation is stable at 37 degree c. atleast 2 months, useful in an implantable drug delivery device
05/30/2000US6068844 Increased resistance to stroke by developing immunologic tolerance to myelin or components thereof
05/30/2000US6068841 Antibodies to Fas-L for treatment of hepatitis
05/30/2000US6068838 Purified multimerase having proteolytic activity, converts von willebrand factor having a singlet structure to von willebrand factor having satellite structure and is active in presence of serine protease and calpin protease inhibitor
05/30/2000US6068837 Mesothelial cell gene therapy
05/30/2000CA2223360C Cyclic peptide compounds and their production process
05/30/2000CA2181566C Compositions and methods using unbound mpl receptor for stimulating platelet production
05/30/2000CA2159326C Method for treating amyloidosis
05/30/2000CA2153071C Derivatized calcitonins
05/30/2000CA2142862C Method for inhibiting hiv replication using il-4
05/30/2000CA2119128C Alleviation of symptoms associated with inflammatory disease states
05/30/2000CA2083333C High dosage topical forms of collagenase
05/30/2000CA2063416C Methods of treating or preventing autoimmune uveoretinitis mammals
05/30/2000CA2019363C Dna and use thereof
05/30/2000CA1341004C Recombinant alzheimer's amyloid protein
05/26/2000CA2252966A1 Viral therapeutics
05/25/2000WO2000029623A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
05/25/2000WO2000029622A2 Nucleic acids containing single nucleotide polymorphisms and methods of use thereof
05/25/2000WO2000029620A1 Methods of facilitating vascular growth
05/25/2000WO2000029609A1 N-terminally truncated her-2/neu protein as a cancer prognostic indicator
05/25/2000WO2000029601A1 A method for depopulating of vertebrate testis and for generation of transgenic species
05/25/2000WO2000029600A1 Systemic viral/ligand gene delivery system and gene therapy
05/25/2000WO2000029599A1 Viral vectors with late transgene expression
05/25/2000WO2000029589A1 Methioninase gene therapy for tumor treatment
05/25/2000WO2000029588A1 Lysozyme fusion proteins in infections
05/25/2000WO2000029584A1 Antibody variants with higher binding affinity compared to parent antibodies
05/25/2000WO2000029583A2 Immunoglobulin superfamily proteins
05/25/2000WO2000029581A1 Human tslp dna and polypeptides
05/25/2000WO2000029580A1 Calcium binding protein
05/25/2000WO2000029578A1 Cloning and characterization of two m-rna transcription factors
05/25/2000WO2000029574A2 Inflammation-associated genes
05/25/2000WO2000029571A1 Gene encoding novel transmembrane protein
05/25/2000WO2000029570A1 Novel protein and utilization thereof
05/25/2000WO2000029569A1 Methods of diagnosing or treating neurological diseases
05/25/2000WO2000029567A1 Recombinant glycoproteins, method for the production thereof, medicaments containing said glycoproteins and use thereof
05/25/2000WO2000029556A2 Identification of glycosphingolipids that promote hiv-1 entry into cells
05/25/2000WO2000029550A2 Low oxygen culturing of central nervous system progenitor cells
05/25/2000WO2000029549A2 Low oxygen culturing of cells
05/25/2000WO2000029447A1 Rhamm antagonist antibodies
05/25/2000WO2000029446A1 Method for inhibiting macrophage infiltration using monoclonal anti-alpha-d-antibodies
05/25/2000WO2000029445A1 Humanized antibody specific for human 4-1bb and pharmaceutical composition comprising same
05/25/2000WO2000029443A1 Contraceptive antibody vaccines
05/25/2000WO2000029440A1 Methods of conversion of interferon isoforms and products thereof
05/25/2000WO2000029439A1 The cxc chemokine h174 and methods for preventing damage to the nervous system
05/25/2000WO2000029438A1 Egf-like nucleic acids and polypeptides and uses thereof
05/25/2000WO2000029437A1 HYPOXIA-INDUCIBLE FACTOR 1α HIF-1α VARIANTS AND METHODS FOR IDENTIFYING HIF-1α MODULATORS
05/25/2000WO2000029435A1 12 human secreted proteins
05/25/2000WO2000029434A2 PNEUMOCOCCAL CHOLINE BINDING PROTEINS, CbpG AND CbpD, DIAGNOSTIC AND THERAPEUTIC USES THEREOF
05/25/2000WO2000029433A2 12-25-kda bacterial proteins and their 116-58 kda polymers for use e.g. in anti-tumor vaccines
05/25/2000WO2000029431A1 Bispecific molecules cross-linking itim and itam for therapy
05/25/2000WO2000029428A2 5t4 tumour-associated antigen for use in tumour immunotherapy
05/25/2000WO2000029426A1 Compositions and methods for controlling plant pests
05/25/2000WO2000029425A1 Physiologically active peptides
05/25/2000WO2000029423A1 G protein-coupled receptor resembling the leukotriene b4 receptor
05/25/2000WO2000029422A1 31 human secreted proteins
05/25/2000WO2000029405A1 Method for preparing (2s)-1-[ (2r,3s)-5- chloro-3-(2- chlorophenyl) -1-(3,4-dimethoxy benzenesulphonyl) -3-hydroxy-2, 3-dihydro-1h- indole-2-carbonyl] pyrrolidine-2- carboxamide
05/25/2000WO2000029043A1 Bioactive prostheses with immunosuppressive, antistenotic and antithrombotic properties
05/25/2000WO2000029029A1 Compositions and methods for producing vascular occlusion
05/25/2000WO2000029020A1 Anti-icam-r antibody-induced apoptosis
05/25/2000WO2000029019A1 Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment
05/25/2000WO2000029015A2 INFLUENCING OF ANGIGENESIS USING CD66a
05/25/2000WO2000029014A1 Method of treating heparin-induced thrombocytopenia
05/25/2000WO2000029013A1 Stable aqueous insulin preparations without phenol and cresol
05/25/2000WO2000029012A2 Methods of alleviating cancer symptoms
05/25/2000WO2000029011A1 Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
05/25/2000WO2000029009A1 Peptides having anti-cancer and anti-inflammatory activity
05/25/2000WO2000029008A2 Hiv-specific t-cell induction
05/25/2000WO2000028997A1 Phospholipase inhibitors for the treatment of cancer
05/25/2000WO2000028996A1 Cosmetic or dermatological use of 7-hydroxylated steroids alone and/or in combination with elastin derived peptides
05/25/2000WO2000028979A1 Dry powder for inhalation
05/25/2000WO2000028977A1 Antioxidant gel for gingival conditions
05/25/2000WO2000028838A1 Calcium fortified juice-based nutritional supplement
05/25/2000WO2000028820A1 DnaB
05/25/2000WO2000028819A1 Yfil pseudouridine synthase
05/25/2000WO2000028818A1 7-transmembrane receptor mouse kiaa0001
05/25/2000WO2000028813A1 Treatment of myelogenous leukemia
1 ... 2388 2389 2390 2391 2392 2393 2394 2395 2396 2397 2398 2399 2400 2401 2402 2403 2404 2405 2406 2407 2408 ... 3163